BARACLUDE 0.5 MG Israel - English - Ministry of Health

baraclude 0.5 mg

bristol - myers squibb, israel - entecavir; entecavir - film coated tablets - entecavir 0.5 mg; entecavir 0.5 mg - entecavir - entecavir - baraclude is indicated for the treatment of chronic hepatitis b virus (hbv) infection in adults with: - compensated liver disease and evidence of active viral replication, and persistently elevated serum alanine aminotransferase (alt) levels. - decompensated liver disease. baraclude is indicated for the treatment of chronic hepatitis b virus (hbv) infection in adults with: - compensated liver disease and evidence of active viral replication, and persistently elevated serum alanine aminotransferase (alt) levels. - decompensated liver disease.

Baraclude European Union - English - EMA (European Medicines Agency)

baraclude

bristol-myers squibb pharma eeig - entecavir - hepatitis b, chronic - antivirals for systemic use, - baraclude is indicated for the treatment of chronic hepatitis b virus (hbv) infection in adults with:compensated liver disease and evidence of active viral replication, persistently elevated serum alanine aminotransferase (alt) levels and histological evidence of active inflammation and/or fibrosis;decompensated liver disease.for both compensated and decompensated liver disease, this indication is based on clinical trial data in nucleoside naive patients with hbeag positive and hbeag negative hbv infection. with respect to patients with lamivudine-refractory hepatitis b.

ENTECAVIR 0.5 Milligram Film Coated Tablet Ireland - English - HPRA (Health Products Regulatory Authority)

entecavir 0.5 milligram film coated tablet

actavis uk limited - entecavir monohydrate - film coated tablet - 0.5 milligram - nucleoside and nucleotide reverse transcriptase inhibitors

ENTECAVIR 1 Milligram Film Coated Tablet Ireland - English - HPRA (Health Products Regulatory Authority)

entecavir 1 milligram film coated tablet

actavis uk limited - entecavir monohydrate - film coated tablet - 1 milligram - nucleoside and nucleotide reverse transcriptase inhibitors

Baraclude 0.5mg tablets United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

baraclude 0.5mg tablets

bristol-myers squibb pharmaceuticals ltd - entecavir monohydrate - tablet - 500microgram

Baraclude 1mg tablets United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

baraclude 1mg tablets

bristol-myers squibb pharmaceuticals ltd - entecavir monohydrate - tablet - 1mg

Entecavir Accord European Union - English - EMA (European Medicines Agency)

entecavir accord

accord healthcare s.l.u. - entecavir - hepatitis b, chronic - antivirals for systemic use, - entecavir accord is indicated for the treatment of chronic hepatitis b virus (hbv) infection in adults with: , compensated liver disease and evidence of active viral replication, persistently elevated serum alanine aminotransferase (alt) levels and histological evidence of active inflammation and/or fibrosis., decompensated liver disease. , for both compensated and decompensated liver disease, this indication is based on clinical trial data in nucleoside naive patients with hbeag positive and hbeag negative hbv infection. with respect to patients with lamivudine-refractory hepatitis b. entecavir accord is also indicated for the treatment of chronic hbv infection in nucleoside naive paediatric patients from 2 to

Entecavir Mylan European Union - English - EMA (European Medicines Agency)

entecavir mylan

mylan pharmaceuticals limited - entecavir monohydrate - hepatitis b - antivirals for systemic use, - entecavir mylan is indicated for the treatment of chronic hepatitis b virus (hbv) infection in adults with: , compensated liver disease and evidence of active viral replication, persistently elevated serum alanine aminotransferase (alt) levels and histological evidence of active inflammation and/or fibrosis., decompensated liver disease. for both compensated and decompensated liver disease, this indication is based on clinical trial data in nucleoside naive patients with hbeag positive and hbeag negative hbv infection. with respect to patients with lamivudine-refractory hepatitis b. entecavir mylan is also indicated for the treatment of chronic hbv infection in nucleoside naive paediatric patients from 2 to